Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

INTRODUCTION: Dapagliflozin is a selective sodium glucose co-transporter 2 inhibitor that improves glycemic control and reduces body weight and systolic blood pressure in patients with type 2 diabetes mellitus (T2DM). Dapagliflozin is effective and well tolerated over 12–24 weeks in Japanese patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Ther
Hlavní autoři: Kaku, Kohei, Maegawa, Hiroshi, Tanizawa, Yukio, Kiyosue, Arihiro, Ide, Yumiko, Tokudome, Takuto, Hoshino, Yuji, Yang, Jisin, Langkilde, Anna Maria
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2014
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4269643/
https://ncbi.nlm.nih.gov/pubmed/25341477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0086-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky